Based on the significant unmet medical need in the treatment of GAD along with the initial clinical data from the Phase 2b ...

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...

Just days after winning FTC approval to take on three of Catalent’s facilities, Novo Nordisk said it is investing DKK 8.5 ...

Find insight on Novo Holdings, Malaysian glove sector and more in the latest Market Talks covering health care.

The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the ...

Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...

【诺和诺德收购Catalent交易已获准完成】 诺和诺德当地时间12月14日宣布，与诺和控股收购美国合同制药商Catalent的审查相关的所有监管成交条件均已满足，双方现在可以自由完成交易。诺和诺德预计收购将在未来几天内完成。

诺和诺德 当地时间12月14日宣布，与诺和控股收购美国合同制药商Catalent的审查相关的所有监管成交条件均已满足，双方现在可以自由完成交易。诺和诺德预计收购将在未来几天内完成。

Johnson & Johnson sues Cigna divisions, McKinsey resolves opioid charges, and numerous FDA approvals affect companies like ...

根据两家公司于2024年12月发布的消息，这项合作的目的是开发一款基于iPS细胞来源的BCMA ...

Catalent Inc. (CTLT) and Novo Holdings A/S announced that the companies have fulfilled all regulatory closing conditions for their ...

当地时间12月14日，诺和诺德宣布，其大股东诺和控股以165亿美元收购美国合同制药商康泰伦特（Catalent）相关的所有监管交割条件均已满足，双方现在可自由完成交易，以及诺和诺德随后从诺和控股收购三个康泰伦特制造基地。诺和诺德预计收购将在未来几天完成。